Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512449 | 0.86 | MEN1 (0.56) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL2365945 | 0.86 | MEN1 (0.56) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL2197329 | 0.84 | MEN1 (0.61) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL375639 | 0.84 | KMT2A (0.57) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL28677764 | 0.84 | MEN1 (0.54) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL12217609 | 0.83 | KMT2A (0.59) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL34473978 | 0.83 | MEN1 (0.53) | KMT2AMEN1LMNAHDAC4CNR2 | |
| SCHEMBL20502533 | 0.83 | MEN1 (0.56) | KMT2AMEN1HDAC4CNR2CRBN | |
| SCHEMBL3093877 | 0.82 | MEN1 (0.68) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL20668648 | 0.82 | KMT2A (0.64) | KMT2AMEN1LMNAHDAC4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | KMT2A 1431/4885MEN1 4301/4885LMNA 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.